Optimization of the Dosage of Flucytosine in Combination with Amphotericin B for Disseminated Candidiasis: a Pharmacodynamic Rationale for Reduced Dosing | Zendy

William Hope | Zendy; Peter Warn | Zendy; Joanne Sharp | Zendy; Paul Reed | Zendy; Brian Keevil | Zendy; Arnold Louie | Zendy; Thomas J. Walsh | Zendy; David W. Denning | Zendy; George L. Drusano | Zendy

Open Access

Optimization of the Dosage of Flucytosine in Combination with Amphotericin B for Disseminated Candidiasis: a Pharmacodynamic Rationale for Reduced Dosing

Author(s) -

William Hope,

Peter Warn,

Joanne Sharp,

Paul Reed,

Brian Keevil,

Arnold Louie,

Thomas J. Walsh,

David W. Denning,

George L. Drusano

Publication year - 2007

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00488-07

Subject(s) - flucytosine , amphotericin b , pharmacodynamics , pharmacology , dosing , pharmacokinetics , medicine , antifungal , dermatology

Amphotericin B and flucytosine (5FC) have an additive effect when used for disseminated candidiasis. Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research